GlassScriptPhysician profile
Muhammad Imtiaz
NPI 1639315435
$14,321.16
in general payments reported to CMS, 2019-2025
42 companies · $2,583 in 2025
The $2,583 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $639 · 2021: $1,399 · 2022: $3,003 · 2023: $3,189 · 2024: $2,732 · 2025: $2,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,958 · Education: $325 · Travel and Lodging: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,958.27 |
| Education | $325.22 |
| Travel and Lodging | $220.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,232.82 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,740.90 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Intuitive Surgical, INC. | $1,462.67 | 2022-2025 | Da Vinci Surgical System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,097.36 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $741.11 | 2022-2025 | Smartvest |
| Genzyme Corporation | $730.34 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $548.57 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $503.46 | 2021-2025 | Prolastin-C Liquid |
| Amgen INC. | $454.54 | 2021-2025 | Tezspire |
| Mallinckrodt Hospital Products INC. | $453.82 | 2022-2025 | Acthar, Terlivaz |
| Actelion Pharmaceuticals US, INC. | $439.15 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Pulmonx Corporation | $425.24 | 2021-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Abbvie INC. | $224.85 | 2023-2025 | |
| Philips North America LLC | $210.15 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Insmed, INC. | $170.08 | 2020-2025 | Arikayce |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $145.36 | 2021-2025 | Winrevair, Keytruda |
| Fujifilm Healthcare Americas Corporation | $144.69 | 2024 | Fujifilm |
| Pfizer INC. | $137.23 | 2021-2025 | |
| Stryker Corporation | $130.88 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $115.00 | 2019 | |
| Foundation Medicine, INC. | $111.60 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $108.66 | 2021-2022 | |
| Shionogi INC | $91.16 | 2024-2025 | Fetroja |
| Verona Pharma, INC. | $78.44 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $78.30 | 2021-2022 | |
| Penumbra, INC. | $78.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $77.45 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.69 | 2021-2023 | Glassia |
| Inogen, INC. | $69.80 | 2025 | |
| Genentech USA, INC. | $62.52 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $53.24 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $48.97 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $46.85 | 2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $46.66 | 2019 | |
| Advanced Respiratory, INC | $35.41 | 2020 | |
| Paratek Pharmaceuticals, INC. | $31.91 | 2019-2023 | Nuzyra |
| Ethicon INC. | $30.77 | 2021 | |
| Resmed Corp | $22.29 | 2019 | |
| United Therapeutics Corporation | $20.07 | 2021 | |
| Vifor Pharma, INC. | $15.89 | 2024 | Veltassa |
| Covis Pharma Gmbh | $15.41 | 2022 | |
| Portola Pharmaceuticals, LLC | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Imtiaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.